Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock Holdings Lifted by State Street Corp

State Street Corp lifted its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 9.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 214,148 shares of the medical instruments supplier’s stock after buying an additional 18,128 shares during the period. State Street Corp’s holdings in Mesa Laboratories were worth $27,809,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Quadrature Capital Ltd acquired a new position in Mesa Laboratories in the third quarter valued at approximately $221,000. PDT Partners LLC acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth approximately $295,000. Captrust Financial Advisors bought a new stake in shares of Mesa Laboratories in the 3rd quarter worth approximately $207,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Mesa Laboratories by 20.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier’s stock valued at $1,312,000 after purchasing an additional 1,708 shares during the period. Finally, Public Sector Pension Investment Board grew its stake in Mesa Laboratories by 1.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 11,461 shares of the medical instruments supplier’s stock worth $1,488,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Insider Buying and Selling

In related news, CEO Gary M. Owens sold 2,518 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the transaction, the chief executive officer now owns 45,888 shares in the company, valued at $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. StockNews.com cut Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Wells Fargo & Company assumed coverage on shares of Mesa Laboratories in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective on the stock. Finally, Evercore ISI boosted their target price on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st.

Mesa Laboratories Stock Up 0.5 %

MLAB opened at $132.08 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $141.17. The stock’s 50 day moving average price is $120.47 and its 200 day moving average price is $116.30. The stock has a market cap of $717.19 million, a P/E ratio of -2.90 and a beta of 0.86.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 29th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date was Friday, November 29th. Mesa Laboratories’s dividend payout ratio is currently -1.40%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.